Xencor (XNCR) Cash from Financing Activities (2013 - 2026)
Xencor (XNCR) reported Cash from Financing Activities of $950000.0 for Q1 2026, down 23.94% year-over-year from $1.2 million in Q1 2025, and down 84.97% quarter-over-quarter from $6.3 million in Q4 2025.
Xencor (XNCR) Cash from Financing Activities (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Cash from Financing Activities data on file, last reported at $950000.0 in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $950000.0, down 23.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.9 million (down 95.97% YoY), and the FY2025 annual result was $8.2 million, down 95.82% from the prior year.
- Cash from Financing Activities slipped to $950000.0 in Q1 2026 per XNCR's latest filing, from $6.3 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $189.9 million in Q3 2024 and troughed at $356000.0 in Q3 2023.
- A 5-year average of $25.1 million and a median of $1.3 million in 2022 frame the typical range for Cash from Financing Activities.
- On a YoY basis, Cash from Financing Activities climbed as much as 53232.58% in 2024 and fell as far as 97.62% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at $1.2 million in 2022, then jumped by 15785.57% to $186.0 million in 2023, then slumped by 97.62% to $4.4 million in 2024, then jumped by 42.65% to $6.3 million in 2025, then slumped by 84.97% to $950000.0 in 2026.
- Business Quant data shows XNCR's Cash from Financing Activities at $950000.0 in Q1 2026, $6.3 million in Q4 2025, and $662000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 7.00 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -600,000.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 53,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -538.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 85,464.43 |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 950,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 950,000.00 |
| Mar 31, 2026 | 950,000.00 |
| Dec 31, 2025 | 6.32 Mn |
| Dec 31, 2025 | 6.32 Mn |
| Jun 30, 2025 | 662,000.00 |
| Jun 30, 2025 | 662,000.00 |
| Mar 31, 2025 | 1.25 Mn |
| Mar 31, 2025 | 1.25 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Sep 30, 2024 | 189.86 Mn |
| Sep 30, 2024 | 189.86 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.79 Mn |
| Dec 31, 2023 | 186.02 Mn |
| Dec 31, 2023 | 186.02 Mn |
| Sep 30, 2023 | 356,000.00 |
| Sep 30, 2023 | 356,000.00 |